Izalpinin

Izalpinin

SCHEMBL7551775

COc1cc(O)c2c(=O)c(O)c(-c3ccccc3)oc2c1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.83
CYP3A4 P08684 5/20 0.75
MAPT P10636 5/20 0.75
MEN1 O00255 4/20 0.75
KMT2A Q03164 4/20 0.75
KDM4E B2RXH2 3/20 0.75
LMNA P02545 3/20 0.75
HSD17B10 Q99714 2/20 0.75
IPMK Q8NFU5 2/20 0.75
IP6K2 Q9UHH9 2/20 0.75
APP P05067 1/20 0.75
THRB P10828 1/20 0.75
AKR1B1 P15121 1/20 0.75
RECQL P46063 1/20 0.75
ELAVL3 Q14576 1/20 0.75
TDP1 Q9NUW8 1/20 0.75
ABCB1 P08183 4/20 0.73
CYP1A1 P04798 4/20 0.73
CYP1A2 P05177 4/20 0.73
CYP1B1 Q16678 4/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Izalpinin SCHEMBL29974286 1.00 MAOA (0.83) MAOACYP3A4MAPTMEN1KMT2A
Rhamnocitrin SCHEMBL29903288 0.91 MAOA (1.00) MAOACYP3A4MAPTMEN1KMT2A
SCHEMBL748643 0.91 MAOA (0.90) MAOACYP3A4MAPTMEN1KMT2A
Rhamnocitrin SCHEMBL1759429 0.91 MAOA (1.00) MAOACYP3A4MAPTMEN1KMT2A
SCHEMBL28536757 0.88 ABCG2 (0.83) MAOACYP3A4MAPTMEN1KMT2A
SCHEMBL38650680 0.88 ABCG2 (0.83) MAOACYP3A4MAPTMEN1KMT2A
SCHEMBL18130384 0.88 ABCB1 (0.83) MAOACYP3A4MAPTMEN1KMT2A
Rhamnetin SCHEMBL7926021 0.87 MEN1 (0.78) MAOACYP3A4MAPTMEN1KMT2A
SCHEMBL777545 0.87 APP (0.73) MAOACYP3A4MAPTMEN1KMT2A
SCHEMBL12640013 0.86 KDM4E (0.79) MAOACYP3A4MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081181-A1 PLANT EXTRACTS FOR TREATMENT OF INCREASED FACIAL VASCULARITY Oriflame Cosmetics AG (CH) 2022-11-02 EP claimed
WO-2021129977-A1 PLANT EXTRACTS FOR TREATMENT OF INCREASED FACIAL VASCULARITY ORIFLAME COSMETICS AG (SE) 2021-07-01 WO claimed
EP-4081181-A1 PLANT EXTRACTS FOR TREATMENT OF INCREASED FACIAL VASCULARITY Oriflame Cosmetics AG (CH) 2022-11-02 EP disclosed
WO-2021129977-A1 PLANT EXTRACTS FOR TREATMENT OF INCREASED FACIAL VASCULARITY ORIFLAME COSMETICS AG (SE) 2021-07-01 WO disclosed
CN-108785200-B Antibacterial, acne-removing and anti-wrinkle silver ion moisturizing mask liquid, mask and preparation method of mask 安徽省银锂子生物科技发展有限公司 2021-05-25 CN disclosed
CN-110251525-A A kind of new application of natural products Echioidin 百世诺(北京)医疗科技有限公司 2019-09-20 CN disclosed
US-20170209499-A1 Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health MANUKA HEALTH NEW ZEALAND LIMITED (NZ) 2017-07-27 US disclosed
US-20150306167-A1 ALPINIA SPP. EXTRACTS FOR TREATING IRRITABLE BOWEL SYNDROME MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) 2015-10-29 US disclosed
US-20150306167-A1 ALPINIA SPP. EXTRACTS FOR TREATING IRRITABLE BOWEL SYNDROME MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) 2015-10-29 US disclosed
CN-104586873-A Application of oroxin A in preparation of medicines for treating cancer UNIV SOOCHOW 2015-05-06 CN disclosed
WO-2014163512-A1 THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF MANUKA HEALTH NEW ZEALAND LIMITED (NZ) 2014-10-09 WO disclosed
WO-2014101873-A1 ALPINIA SPP. EXTRACTS FOR TREATING IRRITABLE BOWEL SYNDROM MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) 2014-07-03 WO disclosed
CN-100581558-C Preparation of blood-activating and pain-stopping capsules ZHONGSHAN PHARMACEUTICAL CO LTD NANJING 2010-01-20 CN disclosed
CN-100484532-C Chinese medicine extract, its production and use in pharmacy NANJING ZHONGSHAN PHARMACEUTIC (CN) 2009-05-06 CN disclosed
CN-1939378-A Preparation of blood-activating and pain-stopping capsules ZHONGSHAN PHARMACEUTICAL CO LT (CN) 2007-04-04 CN disclosed
CN-1939347-A Chinese medicine extract, its production and use in pharmacy ZHONGSHAN PHARMACEUTICAL CO LT (CN) 2007-04-04 CN disclosed
EP-1214308-A2 NOVEL FLAVONOIDS VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS (NL) 2002-06-19 EP disclosed
WO-2001021608-A2 NOVEL FLAVONOIDS VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS (NL) 2001-03-29 WO disclosed
EP-0245931-A2 Nodulation inducing factors LUBRIZOL GENETICS INC. (US) 1987-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170209499-A1 Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health CUTA, DSC1, DACH1 MAOA 4822/4885CYP3A4 3365/4885MAPT 1803/4885
US-20150306167-A1 ALPINIA SPP. EXTRACTS FOR TREATING IRRITABLE BOWEL SYNDROME ALPI, SI, ALPL MAOA 3247/4885CYP3A4 781/4885MAPT 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.